CY1118433T1 - Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης - Google Patents

Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης

Info

Publication number
CY1118433T1
CY1118433T1 CY20171100058T CY171100058T CY1118433T1 CY 1118433 T1 CY1118433 T1 CY 1118433T1 CY 20171100058 T CY20171100058 T CY 20171100058T CY 171100058 T CY171100058 T CY 171100058T CY 1118433 T1 CY1118433 T1 CY 1118433T1
Authority
CY
Cyprus
Prior art keywords
samples
combinations
compounds
inflammatory
sulfylhyl
Prior art date
Application number
CY20171100058T
Other languages
English (en)
Inventor
Niccolò MIRAGLIA
Mauro Rossini
Davide Bianchi
Antonella Trentin
Original Assignee
Gnosis S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnosis S.P.A. filed Critical Gnosis S.P.A.
Publication of CY1118433T1 publication Critical patent/CY1118433T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει συνδυασμούς οι οποίοι περιλαμβάνουν θειική χονδροϊτίνη (CS), ένα ή περισσότερα ένζυμα ή ενζυματικά μίγματα τα οποία διαθέτουν πρωτεολυτική δραστικότητα και σουλφυδρυλικές ενώσεις για την αγωγή και πρόληψη οστεοαρθρίτιδας και σχετιζομένων οξέων και χρόνιων φλεγμονωδών διαδικασιών ή ως διατροφοφαρμακευτικών συνθέσεων για τη διατήρηση της καλής κατάστασης του μυοσκελετικού συστήματος σε ανθρώπους και ζώα. Το χαρακτηριστικό των εν λόγω συνδυασμών είναι ότι αυξάνουν την εντερική απορρόφηση της CS, όταν χορηγούνται από του στόματος. Το αποτέλεσμα των εν λόγω συνδυασμών ασκείται σε μία ευρεία περιοχή μοριακών βαρών της CS, όπου συμπεριλαμβάνονται δείγματα CS με πολύ χαμηλά μοριακά βάρη, τα οποία διαθέτουν ήδη μεγαλύτερη βιοδιαθεσιμότητα εν συγκρίσει προς δείγματα με ένα υψηλότερο μοριακό βάρος. Το αποτέλεσμα ασκείται σε δείγματα CS οποιασδήποτε προέλευσης.
CY20171100058T 2013-01-25 2017-01-17 Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης CY1118433T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000117A ITMI20130117A1 (it) 2013-01-25 2013-01-25 Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
PCT/EP2014/051308 WO2014114706A1 (en) 2013-01-25 2014-01-23 Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate

Publications (1)

Publication Number Publication Date
CY1118433T1 true CY1118433T1 (el) 2017-06-28

Family

ID=47749928

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100058T CY1118433T1 (el) 2013-01-25 2017-01-17 Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης

Country Status (27)

Country Link
US (1) US20150366978A1 (el)
EP (1) EP2948160B1 (el)
JP (1) JP6348123B2 (el)
KR (1) KR102235577B1 (el)
CN (1) CN105101985B (el)
AU (1) AU2014209961B2 (el)
BR (1) BR112015017544B1 (el)
CA (1) CA2899129C (el)
CY (1) CY1118433T1 (el)
DK (1) DK2948160T3 (el)
EA (1) EA030130B1 (el)
ES (1) ES2616017T3 (el)
GE (1) GEP201706673B (el)
HR (1) HRP20170198T1 (el)
HU (1) HUE033162T2 (el)
IL (1) IL240108B (el)
IT (1) ITMI20130117A1 (el)
LT (1) LT2948160T (el)
MX (1) MX359136B (el)
NZ (1) NZ710337A (el)
PH (1) PH12015501474A1 (el)
PL (1) PL2948160T3 (el)
PT (1) PT2948160T (el)
SI (1) SI2948160T1 (el)
UA (1) UA114941C2 (el)
WO (1) WO2014114706A1 (el)
ZA (1) ZA201505322B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106215176A (zh) * 2016-08-22 2016-12-14 安徽瑞达健康产业投资有限公司 一种高效抗炎多酶组合物
CN108741099A (zh) * 2018-06-11 2018-11-06 广州尚天诚品生物科技有限公司 一种有助于关节舒适的营养组合物及其制备方法和应用
KR102231289B1 (ko) * 2018-12-26 2021-03-23 (주)휴온스 고함량 콘드로이틴설페이트 약학 제제 및 이의 제조방법
CN111744018A (zh) * 2019-03-26 2020-10-09 北京福元医药股份有限公司 一种盐酸氨基葡萄糖药物制剂
CN112741272B (zh) * 2021-01-18 2023-02-28 黑龙江中医药大学 一种高含量纳豆激酶的纳豆冻干粉的发酵方法
IT202100030935A1 (it) 2021-12-09 2023-06-09 Fidia Farm Spa Compresse comprendenti condroitin solfato, glucosamina cloridrato e vitamina c per il trattamento di danni cartilaginei, tendinei, ossei

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US5679344A (en) 1995-07-20 1997-10-21 Susan K. Williams Glucosamine composition and method
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
CA2417867C (en) * 2000-07-31 2012-09-11 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
ITMI20012200A1 (it) * 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
JP4466012B2 (ja) * 2003-08-26 2010-05-26 日油株式会社 腸溶性製剤およびその製造方法
JP2006083151A (ja) * 2004-09-16 2006-03-30 Oriza Yuka Kk 骨粗鬆症予防、改善用組成物
JP5462430B2 (ja) * 2006-01-19 2014-04-02 オリザ油化株式会社 抗炎症剤及び鎮痛剤
US8287858B2 (en) 2006-08-10 2012-10-16 Jon Barron Proteolytic enzyme formulations
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
RU2381021C2 (ru) * 2007-11-12 2010-02-10 Леонид Леонидович Клопотенко Зубная паста, содержащая липосомы
ES2705734T3 (es) 2011-05-12 2019-03-26 Gnosis Spa Sulfato de condroitina biotecnológico sulfatado en la posición 4 o 6 en la misma cadena de polisacárido y proceso para la preparación del mismo
KR101788536B1 (ko) 2011-05-20 2017-10-20 그노시스 에스.피.에이. 상어­유사 콘드로이틴 설페이트 및 이의 제조방법
ITMI20120880A1 (it) 2012-05-22 2013-11-23 Gnosis Spa Condroitin 6-solfato biotecnologico a basso peso molecolare dotato di attivita' antiinfiammatoria e antiartritica e suo uso nel trattamento e nella prevenzione dell'osteoartrite

Also Published As

Publication number Publication date
NZ710337A (en) 2019-04-26
JP2016505060A (ja) 2016-02-18
ES2616017T3 (es) 2017-06-09
PH12015501474B1 (en) 2015-09-21
EP2948160B1 (en) 2016-11-16
GEP201706673B (en) 2017-05-25
LT2948160T (lt) 2017-02-10
IL240108A0 (en) 2015-09-24
SI2948160T1 (sl) 2017-02-28
HUE033162T2 (en) 2017-11-28
JP6348123B2 (ja) 2018-06-27
WO2014114706A1 (en) 2014-07-31
BR112015017544B1 (pt) 2023-04-25
KR102235577B1 (ko) 2021-04-06
CN105101985B (zh) 2018-02-23
AU2014209961A1 (en) 2015-08-13
US20150366978A1 (en) 2015-12-24
KR20150111351A (ko) 2015-10-05
CA2899129C (en) 2023-01-17
UA114941C2 (uk) 2017-08-28
MX359136B (es) 2018-09-14
ITMI20130117A1 (it) 2014-07-26
MX2015009544A (es) 2015-11-25
IL240108B (en) 2020-03-31
PL2948160T3 (pl) 2017-05-31
PH12015501474A1 (en) 2015-09-21
HRP20170198T1 (hr) 2017-04-07
DK2948160T3 (en) 2017-02-20
EA030130B1 (ru) 2018-06-29
CA2899129A1 (en) 2014-07-31
EP2948160A1 (en) 2015-12-02
CN105101985A (zh) 2015-11-25
AU2014209961B2 (en) 2018-05-17
PT2948160T (pt) 2017-02-17
ZA201505322B (en) 2016-10-26
BR112015017544A2 (pt) 2017-07-11
EA201591216A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
CY1118433T1 (el) Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1122981T1 (el) Συνθεσεις για διαμορφωση της εκφρασης του c9orf72
CY1122832T1 (el) Σουλφονυλουριες και σχετικες ενωσεις και χρηση αυτων
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123369T1 (el) Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α)
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
BR112017007543A2 (pt) peptídeos com propriedades anti-inflamatórias
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
CY1121384T1 (el) Συνδυαστικη θεραπεια για την αγωγη ανθεκτικων βακτηριακων λοιμωξεων
BR112015032595A2 (pt) inibidores de ido
CY1122813T1 (el) Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds)
BR112017023710A2 (pt) inibidores de histona deacetilase e composições e métodos de uso dos mesmos
CY1125287T1 (el) Δικυκλικοι αναστολεις της αποακετυλασης ιστονης
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CY1123194T1 (el) Νεες αντιβακτηριακες ενωσεις
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
BR112018013761A2 (pt) compostos antiproliferativos e suas composições farmacêuticas e usos
DK3768305T5 (da) Modificerede, onkolytiske adenovira
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома